Taysha Gene Therapies, Inc. [Rocket]

Overview

Taysha Gene Therapies, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
10/05/2023	DEF 14A	Form DEF 14A - Other definitive proxy statements:
08/25/2023	SC 13G	RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in TAYSHA GENE THERAPIES, INC.
08/25/2023	4	Alam Kamran (CFO) has filed a Form 4 on Taysha Gene Therapies, Inc.
08/25/2023	D	Form D - Notice of Exempt Offering of Securities:
08/25/2023	SC 13G	TCG Crossover GP I, LLC reports a 5.9% stake in Taysha Gene Therapies, Inc.
08/24/2023	144	Form 144 - Report of proposed sale of securities:
08/24/2023	8-K	Other Events, Financial Statements and Exhibits  Interactive Data

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20
Revenues	0.0	0.0
Cost of goods sold	0.0	0.0
Gross profit	0.0	0.0
Research and development	131.9	31.9
General and administrative	41.3	11.1
EBIT	-173.3	-43.0
Pre-tax income	-174.5	-60.0
Income taxes	0.0	0.0
Tax rate	0.0%	0.0%
Net income	-174.5	-60.0

Diluted EPS	($4.64)	($3.40)
Shares outstanding (diluted)	37.7	17.7

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy